This funding opportunity aims to accelerate the establishment of effective and reliable biomarkers for Alzheimer's disease (AD) and AD-related dementias (ADRD), supporting analytical and/or clinical validation of biomarkers with rigor consistent with FDA regulatory pathways. The goal is to enable their use in therapy and medical product discovery, clinical development, and clinical practice.
This funding opportunity aims to accelerate the establishment of effective and reliable biomarkers for Alzheimer's disease (AD) and AD-related dementias (ADRD), supporting analytical and/or clinical validation of biomarkers with rigor consistent with FDA regulatory pathways. The goal is to enable their use in therapy and medical product discovery, clinical development, and clinical practice.